AMPH Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 14.83% compared to Amphastar Pharmaceuticals's net margin of 21.68%. Amphastar Pharmaceuticals's return on equity of 19.69% beat Eli Lilly and's return on equity of 78.25%.

Amphastar Pharmaceuticals has a consensus price target of $35.40, signalling upside risk potential of 46.83%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Amphastar Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Amphastar Pharmaceuticals is more attractive than Eli Lilly and.

Amphastar Pharmaceuticals has a beta of 0.784, which suggesting that the stock is 21.583% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amphastar Pharmaceuticals quarterly revenues are $170.5M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Amphastar Pharmaceuticals's net income of $25.3M is lower than Eli Lilly and's net income of $2.8B. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 8.74x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 1.69x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 14.83% compared to Amphastar Pharmaceuticals's net margin of -49.65%. Amphastar Pharmaceuticals's return on equity of 19.69% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Amphastar Pharmaceuticals has a consensus price target of $35.40, signalling upside risk potential of 46.83%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that NovaBay Pharmaceuticals has higher upside potential than Amphastar Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals has a beta of 0.784, which suggesting that the stock is 21.583% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $170.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amphastar Pharmaceuticals's net income of $25.3M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 8.74x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 1.69x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 14.83% compared to Amphastar Pharmaceuticals's net margin of --. Amphastar Pharmaceuticals's return on equity of 19.69% beat Theriva Biologics's return on equity of --.

Amphastar Pharmaceuticals has a consensus price target of $35.40, signalling upside risk potential of 46.83%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Amphastar Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals has a beta of 0.784, which suggesting that the stock is 21.583% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $170.5M, which are larger than Theriva Biologics quarterly revenues of --. Amphastar Pharmaceuticals's net income of $25.3M is higher than Theriva Biologics's net income of -$4.4M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 8.74x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 1.69x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of 14.83% compared to Amphastar Pharmaceuticals's net margin of -93.48%. Amphastar Pharmaceuticals's return on equity of 19.69% beat Viatris's return on equity of -20.24%.

Amphastar Pharmaceuticals has a consensus price target of $35.40, signalling upside risk potential of 46.83%. On the other hand Viatris has an analysts' consensus of $11.7471 which suggests that it could grow by 33.95%. Given that Amphastar Pharmaceuticals has higher upside potential than Viatris, analysts believe Amphastar Pharmaceuticals is more attractive than Viatris.

Amphastar Pharmaceuticals has a beta of 0.784, which suggesting that the stock is 21.583% less volatile than S&P 500. In comparison Viatris has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.265%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.47% to investors and pays a quarterly dividend of $0.12 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $170.5M, which are smaller than Viatris quarterly revenues of $3.3B. Amphastar Pharmaceuticals's net income of $25.3M is higher than Viatris's net income of -$3B. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 8.74x while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 1.69x versus 0.73x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.